



Press release

## Interest for the ZENEO<sup>®</sup> auto-injector from an American pharmaceutical company

Dijon, 15 September 2022

**CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing and soon to market a portfolio of drugs for use in emergency situations,** announces interest for the ZENEO<sup>®</sup> auto-injector from an American pharmaceutical company.

Crossject's ZENEO<sup>®</sup> autoinjector is being tested by an American pharmaceutical company in a drug formulation compatibility study.

This study is part of the early stage development of a rescue therapy for a lifesaving indication with pre-hospital administration by non-medical personnel.

ZENEO<sup>®</sup> components worth \$0.1million have been bought from Crossject by the partner for this initial study.

Patrick Alexandre, Crossject CEO, said: *"We are excited by this new potential cooperation. This innovating drug-device combination would fit perfectly in our mission to save lives."*

Next release: 20 September 2022 (after trading): First-half 2022 results



## Contacts :

### Crossject

Patrick Alexandre

[info@crossject.com](mailto:info@crossject.com)

### Investor relations

#### CIC Market Solutions

Catherine Couanau +33 (0) 1 53 48 81 97

[catherine.couanau@cic.fr](mailto:catherine.couanau@cic.fr)

### Press relations

#### Buzz & Compagnie

Mélanie Voisard +33 (0)3 80 43 54 89

[melanie.voisard@buzzetcompagnie.com](mailto:melanie.voisard@buzzetcompagnie.com)

Christelle Distinguin +33 (0)6 09 96 51 70

[christelle.distinguin@buzzetcompagnie.com](mailto:christelle.distinguin@buzzetcompagnie.com)

## A propos de CROSSJECT • [www.crossject.com](http://www.crossject.com)

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014; it receives funding from BARDA (Biomedical Advanced Research and Development Authority) in the United States and Bpifrance in France.